1. Home
  2. EVC vs CHRS Comparison

EVC vs CHRS Comparison

Compare EVC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entravision Communications Corporation

EVC

Entravision Communications Corporation

HOLD

Current Price

$8.13

Market Cap

335.0M

Sector

Industrials

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.58

Market Cap

296.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVC
CHRS
Founded
1996
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
335.0M
296.8M
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
EVC
CHRS
Price
$8.13
$1.58
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
3.2M
1.3M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
5.35%
N/A
EPS Growth
47.59
472.00
EPS
0.13
N/A
Revenue
$536,034,000.00
N/A
Revenue This Year
N/A
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
$68.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.81
$0.72
52 Week High
$9.40
$2.62

Technical Indicators

Market Signals
Indicator
EVC
CHRS
Relative Strength Index (RSI) 71.18 39.72
Support Level $2.66 $1.55
Resistance Level N/A $1.80
Average True Range (ATR) 0.76 0.11
MACD 0.38 -0.02
Stochastic Oscillator 77.77 2.75

Price Performance

Historical Comparison
EVC
CHRS

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: